Table 2 Main toxicokinetic (TK) parameters of IBI319 after multiple intravenous injections at 1, 10 or 50 mg/kg (mean ± SD, n = 10).

From: Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Dose (mg/kg)

Time

AUC0-t (h·μg/mL)

Cmax (μg/mL)

Tmax (h)

1

Day 1

1405.00 ± 259.33

26.83 ± 2.77

0.41 ± 0.84

Day 22

–

–

–

10

Day 1

15,460.00 ± 23,663.70

245.80 ± 57.31

1.01 ± 2.53

Day 22

542.11 ± 358.75

104.20 ± 50.32

0.02 ± 0.00

50

Day 1

80,710.00 ± 20907.81

1157.00 ± 174.11

0.02 ± 0.00

Day 22

21,743.00 ± 22429.54

1083.90 ± 584.71

0.02 ± 0.00

  1. AUC0-t area under the serum drug concentration-time curve up from time zero to the last measurable concentration, Cmax maximum drug concentration observed in the serum, Tmax time of the first occurrence of Cmax. -: not calculated as the concentration was below detection limit.
Back to article page